Zawawi Ayat, Alghanmi Maimonah, Alsaady Isra, Gattan Hattan, Zakai Haytham, Couper Kevin
Faculty of Applied Medical Sciences, Department of Medical Laboratory Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Special Infectious Agents Unit, King Fahad Medical Research center, Jeddah, Saudi Arabia.
Parasite Epidemiol Control. 2020 Nov;11:e00187. doi: 10.1016/j.parepi.2020.e00187. Epub 2020 Oct 20.
SARS-CoV-2 has spread throughout the world and become the cause of the infectious coronavirus disease 2019 (COVID-19). As low- and middle-income countries shift increasingly to focus on identifying and treating COVID-19, questions are emerging about the impact this shift in focus will have on ongoing efforts to control other infectious diseases, such as malaria. This review discusses how the spread of SARS-CoV-2 in low- and middle-income countries might impact these efforts, focusing in particular on the effects of co-infection and the use of antimalarial drugs used to treat malaria as therapeutic interventions for COVID-19.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）已在全球传播，并成为2019年冠状病毒病（COVID-19）这一传染性疾病的病因。随着低收入和中等收入国家越来越多地将重点转向识别和治疗COVID-19，人们开始质疑这种重点转移将对正在进行的其他传染病防控工作产生何种影响，比如疟疾。本综述讨论了SARS-CoV-2在低收入和中等收入国家的传播可能如何影响这些工作，特别关注合并感染的影响以及用于治疗疟疾的抗疟药物作为COVID-19治疗干预措施的使用情况。
